Patent intelligence · US
US 10517874
sGC stimulators
sGC stimulators
Patent details — US 10517874
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 31, 2019
- Expiration
- Dec 26, 2039
- Applicant
- Cyclerion Therapeutics, Inc.
- Claims
- 17
- CPC classes
- A61K, A61K31/506, A61K31/517, A61K31/519
Quick answer
US 10517874 (sGC stimulators) is held by Cyclerion Therapeutics, Inc.. Status: granted. Granted Dec 31, 2019. Expires Dec 26, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cyclerion Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K31/506, A61K31/517, A61K31/519, A61K31/5377, A61K31/541
More from Cyclerion Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12247025
Processes for preparation of soluble guanylate cyclase stimulators
granted -
US 11834444
Processes for preparation of soluble guanylate cyclase stimulators
granted -
US 11731977
SGC stimulators
granted -
US 11690828
Treatment of CNS diseases with sGC stimulators
granted -
US 11572358
Solid forms of an sGC stimulator
granted -
US 11466015
Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators
granted -
US 11389449
Treatment of metabolic syndrome with an sGC stimulator
granted -
US 11357777
Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)
granted
Frequently asked questions
What is US patent 10517874?
US 10517874 (sGC stimulators) is held by Cyclerion Therapeutics, Inc.. Status: granted. Granted Dec 31, 2019. Expires Dec 26, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10517874?
Cyclerion Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 17 pharmaceutical patents for this assignee.
When does US 10517874 expire?
Our index shows an expiration date of Dec 26, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.